Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

The therapy showed a two-point reduction in total PANSS score at week six against placebo with atypical antipsychotic.

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

US pharma major Bristol Myers Squibb (NYSE: BMY) saw its shares fall 4% in after-hours trading on Tuesday, after it announced ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been recommended by the National ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the ...

CSIO has announced that Gore Mutual Insurance Company has received its eDocs Certification, confirming that the insurer’s ...